GLS-012 / Gloria Pharma, WuXi AppTec - LARVOL DELTA

A phase I/II study to evaluate the safety, tolerability and preliminary efficacy of GLS-012 monotherapy and in combination with zimberelimab in patients with advanced melanoma (Triumph-01) (SITC 2023) - P1/2 | "1, in 14 evaluable patients, stable disease (SD) was observed with 8 patients. Conclusions GLS-012 has acceptable toxicity and shows preliminary antitumor activity in patients with advanced melanoma after progression on standard treatment."

Clinical • Combination therapy • Metastases • Monotherapy • P1/2 data • Melanoma • Oncology • Solid Tumor • LAG3

Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=152 | Not yet recruiting | Sponsor: Guangzhou Gloria Biosciences Co., Ltd.

Metastases • New P1/2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors (clinicaltrials.gov) - P1/2 | N=107 | Recruiting | Sponsor: Guangzhou Gloria Biosciences Co., Ltd.

Combination therapy • Immuno-oncology • Metastases • Monotherapy • New P1/2 trial • Oncology • Solid Tumor